{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["11(2)"],"submitter":["Liu X"],"pubmed_abstract":["<h4>Background</h4>The TACTIC CRC-02 study evaluated the efficacy and safety of tislelizumab, a humanized immunoglobulin G4 monoclonal antibody targeting programmed cell death protein 1, combined with standard XELOX plus bevacizumab as first-line treatment of microsatellite stable/proficient mismatch repair (MSS/pMMR) RAS-mutant metastatic colorectal cancer (mCRC).<h4>Patients and methods</h4>TACTIC CRC-02 was a single-center, single-arm, open-label, phase II trial. Eligible patients had previously untreated, unresectable MSS/pMMR, RAS-mutant mCRC and an Eastern Cooperative Oncology Group performance status of 0 or 1. Patients received intravenous tislelizumab (200 mg/m<sup>2</sup>), bevacizumab (7.5 mg/kg), and oxaliplatin (130 mg/m<sup>2</sup>) on day 1, with oral capecitabine (1000 mg/m"],"journal":["ESMO open"],"pagination":["106056"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12870864"],"repository":["biostudies-literature"],"pubmed_title":["Tislelizumab plus bevacizumab and XELOX as first-line treatment of MSS/pMMR RAS-mutant metastatic colorectal cancer (TACTIC CRC-02): a phase II study."],"pmcid":["PMC12870864"],"pubmed_authors":["Yang L","Zhang H","Ma X","Zhang L","Cao B","Liu X","Zhang W","Yang W","Jiang Z","Ou K","Wang Q","Zhou A","Lu J","Gao L"],"additional_accession":[]},"is_claimable":false,"name":"Tislelizumab plus bevacizumab and XELOX as first-line treatment of MSS/pMMR RAS-mutant metastatic colorectal cancer (TACTIC CRC-02): a phase II study.","description":"<h4>Background</h4>The TACTIC CRC-02 study evaluated the efficacy and safety of tislelizumab, a humanized immunoglobulin G4 monoclonal antibody targeting programmed cell death protein 1, combined with standard XELOX plus bevacizumab as first-line treatment of microsatellite stable/proficient mismatch repair (MSS/pMMR) RAS-mutant metastatic colorectal cancer (mCRC).<h4>Patients and methods</h4>TACTIC CRC-02 was a single-center, single-arm, open-label, phase II trial. Eligible patients had previously untreated, unresectable MSS/pMMR, RAS-mutant mCRC and an Eastern Cooperative Oncology Group performance status of 0 or 1. Patients received intravenous tislelizumab (200 mg/m<sup>2</sup>), bevacizumab (7.5 mg/kg), and oxaliplatin (130 mg/m<sup>2</sup>) on day 1, with oral capecitabine (1000 mg/m","dates":{"release":"2026-01-01T00:00:00Z","publication":"2026 Jan","modification":"2026-07-15T06:15:35.965Z","creation":"2026-06-30T03:22:07.091Z"},"accession":"S-EPMC12870864","cross_references":{"pubmed":["41610691"],"doi":["10.1016/j.esmoop.2025.106056"]}}